AU2002253929A1 - Use of dual h3/m2 antagonists with a bipiperidinic structure in the treatment of cognition deficit disorders - Google Patents

Use of dual h3/m2 antagonists with a bipiperidinic structure in the treatment of cognition deficit disorders

Info

Publication number
AU2002253929A1
AU2002253929A1 AU2002253929A AU2002253929A AU2002253929A1 AU 2002253929 A1 AU2002253929 A1 AU 2002253929A1 AU 2002253929 A AU2002253929 A AU 2002253929A AU 2002253929 A AU2002253929 A AU 2002253929A AU 2002253929 A1 AU2002253929 A1 AU 2002253929A1
Authority
AU
Australia
Prior art keywords
bipiperidinic
antagonists
dual
treatment
deficit disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002253929A
Other languages
English (en)
Inventor
Robert G. Aslanian
John A. Hey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AU2002253929A1 publication Critical patent/AU2002253929A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2002253929A 2001-02-08 2002-02-06 Use of dual h3/m2 antagonists with a bipiperidinic structure in the treatment of cognition deficit disorders Abandoned AU2002253929A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26735201P 2001-02-08 2001-02-08
US60/267,352 2001-02-08
PCT/US2002/003975 WO2002072093A2 (en) 2001-02-08 2002-02-06 Use of dual h3/m2 antagonists with a bipiperidinic structure in the treatment of cognition deficit disorders

Publications (1)

Publication Number Publication Date
AU2002253929A1 true AU2002253929A1 (en) 2002-09-24

Family

ID=23018432

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002253929A Abandoned AU2002253929A1 (en) 2001-02-08 2002-02-06 Use of dual h3/m2 antagonists with a bipiperidinic structure in the treatment of cognition deficit disorders

Country Status (6)

Country Link
US (1) US6906081B2 (OSRAM)
EP (1) EP1408965A2 (OSRAM)
JP (1) JP2004529117A (OSRAM)
AU (1) AU2002253929A1 (OSRAM)
CA (1) CA2436083A1 (OSRAM)
WO (1) WO2002072093A2 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03008356A (es) * 2001-03-13 2003-12-11 Schering Corp Compuestos del tipo no imidazol como antagonistas de histamina h3.
DE60309598T2 (de) * 2002-06-24 2007-09-13 Schering Corp. Als histamin-h3-antagonisten geeignete indolderivate
US20050090527A1 (en) * 2003-01-28 2005-04-28 Schering Corporation Combination of H1, H3 and H4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
WO2005014571A1 (en) * 2003-07-18 2005-02-17 Glaxo Group Limited Substituted piperidines as histamine h3 receptor ligands
GB0420831D0 (en) * 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
US9132135B2 (en) * 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
CN101044200A (zh) * 2004-09-24 2007-09-26 巴尔的摩马里兰大学 治疗有机磷中毒的方法
US8541452B2 (en) * 2005-10-06 2013-09-24 Guy Chouinard Method for treating binge-eating disorder
US7728031B2 (en) 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
RU2486187C2 (ru) 2007-09-11 2013-06-27 Эбботт Лэборетриз N-ОКСИДЫ ОКТАГИДРО-ПИРРОЛО[3,4-b]ПИРРОЛА
EP4088717A1 (en) * 2008-03-27 2022-11-16 Chase Pharmaceuticals Corporation Use and composition for treating dementia
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
KR20200065113A (ko) 2012-09-05 2020-06-08 체이스 파마슈티칼스 코포레이션 항콜린 신경보호 조성물 및 그 방법
EP4251148A1 (en) * 2020-11-27 2023-10-04 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2624734A (en) * 1950-04-29 1953-01-06 Hoffmann La Roche Bipiperidine derivatives
GB8916947D0 (en) 1989-07-25 1989-09-13 Smith Kline French Lab Medicaments
GB9115740D0 (en) 1991-07-20 1991-09-04 Smithkline Beecham Plc Medicaments
US5633250A (en) 1991-12-18 1997-05-27 Schering Corporation Imidazoylalkyl substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
NZ246441A (en) 1991-12-18 1996-02-27 Schering Corp Imidazol or imidazolalkyl substituted with a 4 or 5 membered nitrogen containing heterocycle, preparation and pharmaceutical compositions thereof
US5807872A (en) 1992-12-16 1998-09-15 Schering Corporation Imidazoylalkyl substituted with a six membered nitrogen containing heterocyclic ring
US5352707A (en) 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
US5446057A (en) 1993-09-24 1995-08-29 Warner-Lambert Company Substituted tetrahydropyridine and piperidine carboxylic acids as muscarinic antagonists
NZ276883A (en) 1993-11-15 1998-08-26 Schering Corp 1h-imidazol-4-yl)alkyl]benzene derivatives
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US5935958A (en) 1996-07-01 1999-08-10 Schering Corporation Muscarinic antagonists
US5952349A (en) 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
US5977138A (en) 1996-08-15 1999-11-02 Schering Corporation Ether muscarinic antagonists
US6034251A (en) 1997-11-07 2000-03-07 Schering Corporation Phenyl-alkyl-imidazoles
US5990147A (en) * 1997-11-07 1999-11-23 Schering Corporation H3 receptor ligands of the phenyl-alkyl-imidazoles type
US6066636A (en) 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
US6100279A (en) 1998-11-05 2000-08-08 Schering Corporation Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom
US6294554B1 (en) 1999-09-22 2001-09-25 Schering Corporation Muscarinic antagonists

Also Published As

Publication number Publication date
WO2002072093A2 (en) 2002-09-19
EP1408965A2 (en) 2004-04-21
CA2436083A1 (en) 2002-09-19
WO2002072093A3 (en) 2004-01-22
US20020151565A1 (en) 2002-10-17
US6906081B2 (en) 2005-06-14
JP2004529117A (ja) 2004-09-24

Similar Documents

Publication Publication Date Title
IL187528A0 (en) Use of pyrimidine compounds in the manufacture of medicaments
AU2003300515A8 (en) Titanium dioxide coated with silicon dioxide
IL159347A0 (en) Arylamines for the treatment of conditions associated with gsk-3
PT2266594E (pt) Vegf para utilização no tratamento de distúrbios do sistema nervoso central
IL175055A0 (en) Combinations useful for the treatment of neuronal disorders
AU2003233583A1 (en) Oral lactoferrin in the treatment of respiratory disorders
HUP0401023A3 (en) Use of flibanserin in the treatment of sexual disorders
AU2002334870B8 (en) Combinations for the treatment of immunoinflammatory disorders
IL157145A0 (en) Use of dc23 antagonists for the treatment of neoplastic disorders
PL374006A1 (en) Treatment involving dkk-1 or antagonists thereof
AU2003255993A1 (en) Diazabicyclic compounds useful in the treatment of cns and other disorders
AU2003258145A8 (en) Substituted phenylindoles for the treatment of hiv
PL369822A1 (en) Use of endothelin receptor antagonists in the treatment of tumour diseases
PL365482A1 (en) Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine
WO2002072093A3 (en) Use of dual h3/m2 antagonists with a bipiperidinic structure in the treatment of cognition deficit disorders
GB0128674D0 (en) Treatment of sleep disorders and the like
IL160782A0 (en) USE OF hCG IN THE MANUFACTURE OF A MEDICAMENT
PL375564A1 (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma
IL168782A (en) Enantiomer (-) of tenatoprazole and its therapeutic use
IL150290A0 (en) The use of mirtazapine for the treatment of sleep disorders
IL160781A0 (en) Use of lh in the manufacture of a medicament
HRP20041160A2 (en) Novel combination for the treatment of airway disorders
IL164951A0 (en) The treatment of pain with lfendropil
AU2003269257A1 (en) Use of cap-1 for the therapy of asthma
GB0209704D0 (en) The rechargeable sauce jug

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase